Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002717 · ClinicalTrials.gov registry record · Phase 3
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT00002717: Completed Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, sponsored by Gynecologic Oncology Group.
NCT00002717 is a Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 324 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002717, a Phase 3 study of Ovarian Cancer and Primary Peritoneal Cavity Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of paclitaxel plus cisplatin in treating patients who have residual disease after surgery to remove stage III or stage IV ovarian cancer or primary peritoneal cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Women's Cancer Center - Palo Alto
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
- CCOP - Central Illinois - Decatur
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Colorado
- University of Colorado Cancer Center - Denver
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University Hospital - Atlanta - Atlanta
Hawaii
- MBCCOP - Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 1996-03 |
| Phase | Phase 3 |
What the finished NCT00002717 record still lists
NCT00002717 is an interventional study that assigns participants to a tested intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.
NCT00002717 names 20 study sites across 14 states, led by California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002717 about?
NCT00002717 is a clinical study titled "Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phas...
What is the current status of trial NCT00002717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 1996-03.
What conditions does trial NCT00002717 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00002717?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00002717?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002717 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002717's enrollment target sits among peer trials
324 66th of 322 higher than 257 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia